Supernus Pharmaceuticals Inc 2026年季度报告

(Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period fromtoCommission File Number: 001-35518 SUPERNUS PHARMACEUTICALS,INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction ofincorporation or organization) (Address of principal executive offices) (Registrant's telephone number, including area code) Indicate by check mark whether the registrant: (1)has filed all reports required to be filed by Section13 or 15(d)of the SecuritiesExchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant was required to file such reports),and (2)has been subject to such filing requirements for the past 90days.☒Yes☐No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).☒Yes No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smallerreporting company," and "emerging growth company" in Rule12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section13(a)of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).☐Yes☒NoSecurities registered pursuant to Section12(b)of the Exchange Act SUPERNUS PHARMACEUTICALS,INC.FORM10-Q — QUARTERLY REPORTFOR THE QUARTERLY PERIOD ENDED June 30, 2026 PARTI — FINANCIAL INFORMATIONItem1. Unaudited Condensed Consolidated Financial StatementsCondensed Consolidated Balance Sheets3Condensed Consolidated Statements of Earnings (Loss)4Condensed Consolidated Statements of Comprehensive Earnings (Loss)5Condensed Consolidated Statements of Changes in Stockholders'Equity6Condensed Consolidated Statements of Cash Flows8Notes to Condensed Consolidated Financial Statements9Item2. Management's Discussion and Analysis of Financial Condition and Results of Operations34Item3. Quantitative and Qualitative Disclosures about Market Risk44Item4. Controls and Procedures45PARTII — OTHER INFORMATIONItem1. Legal Proceedings45Item1A. Risk Factors52Item2. Unregistered Sales of Equity Securities and Use of Proceeds52Item3. Defaults Upon Senior Securities52Item4. Mine Safety Disclosures52Item5. Other Information52Item6. Exhibits53SIGNATURES54 Supernus Pharmaceuticals,Inc.Condensed Consolidated Balance Sheets(in thousands, except share and per share data) Supernus Pharmaceuticals,Inc.Condensed Consolidated Statements of Earnings (Loss)(in thousands, except share and per share data) Supernus Pharmaceuticals,Inc.Condensed Consolidated Statements of Changes in Stockholders' Equity(unaudited, in thousands, except share data) See accompanying notes. Supernus Pharmaceuticals,Inc.Notes to Condensed Consolidated Financial Statements (unaudited) 1.Business Organization Supernus Pharmaceuticals, Inc. (the Company, seeConsolidationin Note 2,Summary of Significant Accounting Policies) is abiopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS)diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder(ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartumdepression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a broad range of novelproduct candidates for CNS disorders. The Company has nine commercial products that it markets in the United States (U.S.): Qelbree , GOCOVRI , Oxtellar XR ,Trokendi XR , APOKYN , XADAGO , MYOBLOC , ONAPGO(formerly known as SPN-830), and ZURZUVAE(acquiredthrough the acquisition of Sage Therapeutics, Inc.). The Company does not directly market its products outside the U.S.®®®®®®®TM® Merger of Equals with Indivior Pharmaceuticals, Inc. Refer to Note 18, Subsequent Events. 2.Summary of Significant Accounting Policies Basis of Presentation The Company's unaudited condensed consolidated financial statements have been prepared in accordance with therequirements of the U.S. Securities and Exchange Commission (SEC) for interim financial information. As permitted under GenerallyAccepted Accounting Principles in the United States (U.S. GAAP), certain notes and oth